ArticleJournal of cellular and molecular medicine2025
Circular RNA Rftn1 Promotes Cardiac Hypertrophy In Vitro and In Vivo by Sponging miRNA-1192 to Upregulate Tripartite Motif Protein 25 and 41.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Emerging Role and Potential Therapeutic Application of TRIM Proteins in Cardiovascular Diseases.Biomolecules · 2026Review
- Circular RNA Rftn1 Promotes Cardiac Hypertrophy In Vitro and In Vivo by Sponging miRNA-1192 to Upregulate Tripartite Motif Protein 25 and 41.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
To verify the role of circular RNA circRftn1 in cardiac hypertrophy and elucidate its potential mechanism via the microRNA-1192-tripartite motif 25 and 41 (miR1192-TRIM25/TRIM41) axis. A mouse model of cardiac hypertrophy was established via abdominal aortic coarctation surgery. An in vitro cell model was generated using neonatal mouse ventricular cardiomyocytes (NMVCs) co-cultured with angiotensin II. Differentially expressed circular RNAs (circRNAs) were identified using next-generation sequencing, and potential target microRNAs (miRNAs) and downstream messenger RNAs (mRNAs) were predicted using bioinformatic analysis. Reverse transcription quantitative polymerase chain reaction and western blotting were used to evaluate the expression of myocardial-associated molecules at the transcriptional and translational levels, respectively. Expression of regulatory molecules was assessed after transfection with small interfering RNAs (siRNAs) or co-culture with miRNA mimics. Dual-luciferase reporter assays were performed to validate interactions between circRNAs and miRNAs. circRftn1 expression was significantly elevated both in vivo and in vitro. Concurrently, the expression of miR-1192 was decreased, whereas its target mRNAs TRIM25 and TRIM41 were markedly upregulated. Knockdown of circRftn1 via siRNA transfection reversed cardiac hypertrophy and led to opposing expression trends of miR-1192 and TRIM25/TRIM41. Dual-luciferase reporter assays confirmed the sponge-like interaction between circRftn1 and miR-1192. By co-culturing NMVCs with miR-1192 mimics, its targets TRIM25/TRIM41 showed significant decreases. Moreover, NF-κB signalling pathway appeared to be involved, as the expression of the p65 subunit paralleled that of circRftn1. circRftn1 may promote cardiac hypertrophy by modulating the miR-1192-TRIM25/TRIM41 axis and NF-κB p65 pathway potentially serving as a downstream pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.